Money never sleeps pal. I just made $800,000 in Hong Kong gold. It's been wired to you -- play with it. You done good, but you gotta keep doing good.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buy in Fear Winks!! Just like fall of 08.. All the Big Boyz bought up stocks for dollars and since most have rebounded for a nice reward!
Everything is RED Today Except GOLD... Todays Drop on Low Volume has nothing to do with anything But some scared holders
I'll say it again. Will see $1 before we see .75 again......
Wow they got Beat and People Bailing on this one today... Hope my Phone stays working........
Holding up Very strong today in a down market!
Its Summer and trading over $2.40...
Antares Pharma to Host Second Quarter 2011 Earnings Call
Antares (AMEX:AIS)
Intraday Stock Chart
Today : Tuesday 2 August 2011
Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will release its second quarter 2011 financial results after the market closes on Monday, August 8, 2011, and host a conference call shortly thereafter at 4:30 p.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, CFO and President of the Parenteral Products Division, will host the call.
Interested parties may participate in the conference call by dialing 877-941-6009 (US) or 480-629-9645 (international), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 p.m. ET (Eastern Time) on August 22, 2011 by dialing 800-406-7325 (US) or 303-590-3030 (international), and entering the access code 4459539. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's lead product candidate is Anturol®, an oxybutynin ATD™ gel that is currently under review by the FDA for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares also has a partnership with BioSante that includes LibiGel® (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.
Great Entry Point Boss... You will be happy within 30 days
News for 'IGXT' - (IntelGenx Announces Successful Pre-Approval Inspection of its Lead Product CPI-300)
Inc. ("Pillar5") successfully passed a pre-approval inspection by the U.S. Food
and Drug Administration (FDA) for IntelGenx' lead product, CPI-300, a novel
antidepressant, with a high strength of bupropion hydrochloride (HCl), which is
the active ingredient in Wellbutrin XL(R).
Pillar5, the contract manufacturing organization ("CMO") selected by IntelGenx
for the manufacture of CPI-300, successfully responded to all queries from the
FDA for its pre-approval site inspection. As expected, the inspection lasted 4
days and concluded with no Form 483 being issued. Form 483 lists observations
made by the FDA representative(s) during the inspection of a facility. Such
observations are inspectional observations, and do not represent a final Agency
determination regarding a facility's compliance.
"First and foremost, we would like to congratulate Pillar5 on this excellent
achievement," said Dr. Horst G. Zerbe, President and Chief Executive Officer of
IntelGenx. "We are very excited to have passed another important milestone in
our end eavors to bring CPI-300 to market and hopefully make this proprietary
product available to patients who suffer from major depressive disorder."
IntelGenx recently submitted its reply to a "Complete Response Letter" issued in
February 2010 by the FDA after its review of IntelGenx' New Drug Application
(NDA) submission for CPI-300. IntelGenx' reply addressed the two main issues
identified by the FDA in the Complete Response Letter, namely the qualification
of a commercial manufacturing site and the food effect, which was observed both
in CPI-300 and the reference product. FDA has accepted IntelGenx' submission and
has established November 13, 2011 as its target action date under the
Prescription Drug User Fee Act ("PDUFA").
As announced on May 4, 2010, IntelGenx has an ownership stake in Pillar5,
representing 10% of the issued and outstanding shares of Pillar5.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral
controlled-release products as well as novel rapidly disintegrating delivery
systems. IntelGenx uses its unique multiple layer delivery system to provide
zero-order release of active drugs in the gastrointestinal tract. IntelGenx has
also developed novel delivery technologies for the rapid delivery of
pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx' research and development pipeline
includes products for the treatment of severe depression, hypertension, erectile
dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder,
idiopathic pulmonary fibrosis, allergies and pain management. More information
is available about the company at www.intelgenx.com.
About Pillar5:
Pillar5 Pharma Inc. is a private company based in Arnprior, Ontario. The
Arnprior manufacturing facility was established in 1956 by Pfizer and has been
operated by Pillar5 since 2009. With nearly 100 employees, the facility has a
long-standing record of manufacturing quality product for the pharmaceutical
industry and "a foundation of excellence". With millions of dollars in
investment over the past many years, the Arnprior manufacturing facility is
equipped with state-of-the-art equipment, infrastructure and processes, along
with proven expertise in the manufacturing and packaging of oral solid and
sterile ophthalmic products.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating
results and business prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, as amended,
and Section 27A of the Securities Act of 1933, as amended. These statements
include, but are not limited to, statements about IntelGenx' plans, objectives,
expectations, strategies, intentions or other characterizations of future events
or circumstances and are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "could,"
"would," and similar expressions. All forward looking statements are expressly
qualified in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and uncertainties,
IntelGenx' actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those discussed
under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for
the fiscal year ended December 31, 2010, filed with the United States Securities
and Exchange Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes
no obligation to updat e any such forward-looking statements.
SOURCE: IntelGenx Corp.
Multi Bagger Here on SNGX..............
NORTH IT IS WINKS!! OLE PAL!
I just Grabbed some shares here of AMRN... Hope to see some Upside soon...
Statement of Changes in Beneficial Ownership (4)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Melchers Bernd Josef 2. Issuer Name and Ticker or Trading Symbol
IntelGenx Technologies Corp. [ IGXT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
KAISER FRIEDRICH PROMENADE 3. Date of Earliest Transaction (MM/DD/YYYY)
7/26/2011
(Street)
BAD HOMBURG V.D. HOEHE, 2M 61348
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock ($0.00001 par value) 7/26/2011 P 20000 A $0.81 45000 D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options (Right to buy) (1) (1) (1) Common Stock 100000 100000 D
Explanation of Responses:
( 1) Comprised of the following: a) 25,000 Options at a conversion price of $0.61; Exercisable: 11/24/2009; Expiring: 11/24/2014. b) 75,000 Options at a conversion price of $0.45; Exercisable: 05/17/2010; Expiring: 05/17/2015.
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Melchers Bernd Josef
KAISER FRIEDRICH PROMENADE
BAD HOMBURG V.D. HOEHE, 2M 61348 X
Signatures
/s/ Bernd Josef Melchers 7/29/2011
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed
OHH YA!! WINKS IS HERE
BIG MONEY BUYS HERE!!
They need to stop raising this once and for all and come up with a spending cut. Next year will just be that much more in debt...
Were on a sinking shop but when it gets low enough they sink quick!!
Hey Broski!! Now I know the Big $$ is here. Wish I got more.. LOL!
Some Nice Volume here Folks today.. Glad I got mine early..
The Debt deal is Passed but in a Nut Shell I Dont think alot or people are happy with the deal
I just added 20k shares here... Looking for some Break out!!
Good Morning Everybody.........................
Its looks to be in a consolidation mode right now
IM HOLDING TO MYSTATEMENT AT .75
Alot of buyers stacked up around .77 and .78
No Doubt winks!!
NO RISK NO REWARD!!!!!! GOTTA BE IN IT TO WIN IT!!!!!
Will see a $1 before we see .75 here winks........ Just Like DRL alittle consolidation and then Higher Highs and Higher lows
Notice of Effectiveness (EFFECT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
NOTICE OF EFFECTIVENESS
Effective Date: July 22, 2011
Form: S-1
CIK: 0001098880
Company Name: IntelGenx Technologies Corp.
File Number: 333-175465
Intelgenx Technologs (OTCBB:IGXT)
Historical Stock Chart
1 Year : July 2010 to July 2011
Intelgenx Technologs (OTCBB:IGXT)
Intraday Stock Chart
Today : Monday 25 July 2011
Hoping to see the Consolidation over and time to move up again..
Current report filing (8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported June 28, 2011
THE LUBRIZOL CORPORATION
(Exact name of registrant as specified in its charter)
Ohio 1-5263 34-0367600
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
29400 Lakeland Boulevard, Wickliffe, Ohio 44092-2298
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (440) 943-4200
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 8.01 Other Events
On June 28, 2011, the Company announced that the board of directors approved the payment on September 9, 2011, of a dividend of $.36 per share to shareholders of record on August 10, 2011. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibit. The following exhibit is filed herewith:
99.1 Press Release of The Lubrizol Corporation, dated June 28, 2011.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
2 weeks Max Winks and we should be using $1 as support levels here..
GOOD MORNING EVERYBODY!!!!!
No Worries around these levels. 4 Months from now this will be a 5 bagger!
Were Green So Far! Just soft on the Volume!
Nice Day of Trading. Yesterday might have been the end of the cheap shares on the dip...
Looks Like a Nice Solid Play to Come from here (AIS)
Entire Marketis RED TODAY. Great Pull back to add some if needed.. Wont stay down long
Cyclacel Pharmaceuticals Amends Its Sapacitabine License Agreement With Daiichi-Sankyo
Cyclacel Pharmaceuticals, Inc. (MM) (NASDAQ:CYCC)
Intraday Stock Chart
Today : Monday 18 July 2011
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that effective July 11, 2011, Cyclacel Limited, a wholly-owned subsidiary of the Company, entered into an amendment of its license agreement, dated September 10, 2003 between Cyclacel Limited and Daiichi Sankyo Company, Limited ("Daiichi Sankyo") relating to certain rights which Cyclacel Limited has licensed from Daiichi Sankyo with regard to the Company's sapacitabine drug.
Pursuant to the amendment and taking into consideration the investment that the Company has made in progressing the development of sapacitabine, Daiichi Sankyo has irrevocably waived a termination right it possessed under a provision of the License Agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least one country by September 2011, and has released the Company from all claims and liability of any kind arising under such provision. The amendment further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net sales of sapacitabine realized.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
© Copyright 2011 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals
GOOD MORNING MR WINKS!!
NBA lays off about 114 league employees
By BRIAN MAHONEY, AP Basketball Writer
Jul 14, 7:09 pm EDT
NEW YORK (AP)—The NBA laid off about 114 people over the last two days, planned cost-cutting moves that a league spokesman said Thursday are “not a direct result of the lockout.”
The laid off employees represent about 11 percent of the league office workforce in New York, New Jersey and internationally.
Spokesman Mike Bass told The Associated Press the layoffs are “not a direct result of the lockout but rather a response to the same underlying issue; that is, the league’s expenses far outpace our revenues.”
“The roughly 11 percent reduction in headcount from the league office is part of larger cost-cutting measures to reduce our costs by $50 million across all areas of our business,” Bass said.
The league said it lost $300 million this season after losing hundreds of millions in each previous year of the collective bargaining agreement that expired at the end of the day June 30.
Owners locked out the players after the sides remained far apart in their final proposals. Commissioner David Stern said at the time it was too early to think about how it could affect staff, but acknowledged that the league would “have to go back and look at everything now with our operations.”
But the reductions had already begun. The NBA and teams had trimmed staff by about 275 since October 2008, either through layoffs or by leaving positions vacant when employees departed.
The league has also cut administrative costs, travel and new technology. It consolidated offices in Europe and Asia, closing offices in Paris and Tokyo, and is shutting down the studio in Secaucus, N.J. where it annually holds the draft lottery. The NBA Store on 5th Ave. in New York has been closed, though the league has said it will reopen in another location.
Already at least two teams, Detroit and Charlotte, have cut staff since the work stoppage was announced exactly two weeks ago. Stern said that day a lockout “has a very large impact on a lot of people, many of whom or most of whom are not associated with either side.”
Follow Brian Mahoney on Twitter: http://www.twitter.com/Briancmahoney
--------------------------------------------------------------------------------